Barinthus Biotherapeutics plc. also files under VACC; those filings are included.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 10, 2025 | Phillips Anne M. | Director | Grant(A) | 20K | — | $0 |
| Jun 10, 2025 | Dawes Karen A | Director | Grant(A) | 20K | — | $0 |
| Jun 10, 2025 | Wright Robin | Director | Grant(A) | 20K | — | $0 |
| Jun 10, 2025 | Hammacher Alex | Director | Grant(A) | 20K | — | $0 |
| Jun 10, 2025 | Scheeren Joseph | Director | Grant(A) | 20K | — | $0 |
| Jun 10, 2025 | Morgon Pierre A. | Director | Grant(A) | 20K | — | $0 |
| Feb 3, 2025 | Enright William | Chief Executive Officer, Director | Grant(A) | 600K | — | $0 |
| Feb 3, 2025 | Brown Gemma | Chief Financial Officer | Grant(A) | 160K | — | $0 |
| Feb 3, 2025 | Hooftman Leon | Chief Medical Officer | Grant(A) | 140K | — | $0 |
| Feb 3, 2025 | Griffiths Graham | Chief Business Officer | Grant(A) | 200K | — | $0 |
| Jun 3, 2024 | Hooftman Leon | Chief Medical Officer | Grant(A) | 195K | — | $0 |
| May 10, 2024 | Dawes Karen A | Director | Grant(A) | 20K | — | $0 |
| May 10, 2024 | Phillips Anne M. | Director | Grant(A) | 20K | — | $0 |
| May 10, 2024 | Wright Robin | Director | Grant(A) | 20K | — | $0 |
| May 10, 2024 | Morgon Pierre A. | Director | Grant(A) | 20K | — | $0 |
| May 10, 2024 | Hammacher Alex | Director | Grant(A) | 20K | — | $0 |
| May 10, 2024 | Scheeren Joseph | Director | Grant(A) | 20K | — | $0 |
| Jan 2, 2024 | Brown Gemma | Chief Financial Officer | Grant(A) | 193K | — | $0 |
| Jan 2, 2024 | Enright William | Chief Executive Officer, Director | Grant(A) | 444K | — | $0 |
| Jan 2, 2024 | Griffiths Graham | Chief Business Officer | Grant(A) | 97K | — | $0 |
| Jan 2, 2024 | Pelletier Nadege | Chief Scientific Officer | Grant(A) | 105K | — | $0 |
| Jun 26, 2023 | Scheeren Joseph | Director | Buy(P) | 10K | $2.44 | $24K |
| May 25, 2023 | Wright Robin | Director | Buy(P) | 14K | $2.66 | $37K |
| May 11, 2023 | Dawes Karen A | Director | Grant(A) | 19K | — | $0 |
| May 11, 2023 | Hammacher Alex | Director | Grant(A) | 19K | — | $0 |
| May 11, 2023 | Morgon Pierre A. | Director | Grant(A) | 19K | — | $0 |
| May 11, 2023 | Phillips Anne M. | Director | Grant(A) | 19K | — | $0 |
| May 11, 2023 | Scheeren Joseph | Director | Grant(A) | 19K | — | $0 |
| May 11, 2023 | Wright Robin | Director | Grant(A) | 19K | — | $0 |
| Mar 27, 2023 | Enright William | Chief Executive Officer, Director | Sell(S) | 15K | $2.42 | $36K |
| Feb 1, 2023 | Pelletier Nadege | Chief Scientific Officer | Grant(A) | 485K | — | $0 |
| Jan 3, 2023 | Enright William | Chief Executive Officer, Director | Grant(A) | 440K | — | $0 |
| Jan 3, 2023 | Griffiths Graham | Chief Business Officer | Grant(A) | 105K | — | $0 |
| Jan 3, 2023 | Evans Thomas George | Fmr Chief Scientific Officer | Grant(A) | 125K | — | $0 |
| Jan 3, 2023 | Marshall Margaret | Chief Medical Officer | Grant(A) | 60K | — | $0 |
| Jan 3, 2023 | Ellis Christopher | Chief Operating Officer | Grant(A) | 105K | — | $0 |
| Jan 3, 2023 | Brown Gemma | Chief Financial Officer | Grant(A) | 33K | — | $0 |
| Sep 30, 2022 | M&G Investment Management Ltd | 10% Owner | Other(J) | 4.1M | — | $0 |
| Sep 30, 2022 | M&G Alternatives Investment Management Ltd | 10% Owner | Other(J) | 4.1M | — | $0 |
| Sep 26, 2022 | Brown Gemma | Chief Financial Officer | Grant(A) | 334K | — | $0 |
| Aug 25, 2022 | Ellis Christopher | Chief Operating Officer | Option exercise(M) | 39K | — | $0 |
| Aug 25, 2022 | Griffiths Graham | Chief Business Officer | Sell(S) | 10K | $7.39 | $74K |
| Aug 25, 2022 | Ellis Christopher | Chief Operating Officer | Sell(S) | 14K | $5.69 | $81K |
| Aug 25, 2022 | Ellis Christopher | Chief Operating Officer | Option exercise(M) | 39K | — | $0 |
| Aug 25, 2022 | Ellis Christopher | Chief Operating Officer | Sell(S) | 25K | $7.07 | $177K |
| Aug 24, 2022 | Ellis Christopher | Chief Operating Officer | Sell(S) | 450 | $4.78 | $2K |
| Aug 24, 2022 | Ellis Christopher | Chief Operating Officer | Option exercise(M) | 450 | — | $0 |
| Aug 24, 2022 | Ellis Christopher | Chief Operating Officer | Option exercise(M) | 450 | — | $0 |
| Aug 18, 2022 | Ellis Christopher | Chief Operating Officer | Sell(S) | 2K | $4.84 | $11K |
| Aug 18, 2022 | Ellis Christopher | Chief Operating Officer | Option exercise(M) | 2K | — | $0 |
| Aug 18, 2022 | Ellis Christopher | Chief Operating Officer | Option exercise(M) | 2K | — | $0 |
| Aug 17, 2022 | Griffiths Graham | Chief Business Officer | Sell(S) | 500 | $4.76 | $2K |
| Aug 17, 2022 | Ellis Christopher | Chief Operating Officer | Option exercise(M) | 649 | — | $0 |
| Aug 17, 2022 | Ellis Christopher | Chief Operating Officer | Option exercise(M) | 649 | — | $0 |
| Aug 17, 2022 | Ellis Christopher | Chief Operating Officer | Sell(S) | 649 | $4.77 | $3K |
| Aug 16, 2022 | Ellis Christopher | Chief Operating Officer | Option exercise(M) | 2K | — | $0 |
| Aug 16, 2022 | Griffiths Graham | Chief Business Officer | Sell(S) | 1K | $4.82 | $6K |
| Aug 16, 2022 | Ellis Christopher | Chief Operating Officer | Option exercise(M) | 2K | — | $0 |
| Aug 16, 2022 | Ellis Christopher | Chief Operating Officer | Sell(S) | 2K | $4.78 | $11K |
| Aug 15, 2022 | Ellis Christopher | Chief Operating Officer | Option exercise(M) | 5K | — | $0 |
| Aug 15, 2022 | Griffiths Graham | Chief Business Officer | Sell(S) | 2K | $4.75 | $11K |
| Aug 15, 2022 | Ellis Christopher | Chief Operating Officer | Option exercise(M) | 5K | — | $0 |
| Aug 15, 2022 | Ellis Christopher | Chief Operating Officer | Sell(S) | 5K | $4.76 | $25K |
| Aug 12, 2022 | Griffiths Graham | Chief Business Officer | Sell(S) | 5K | $4.50 | $23K |
| Jun 28, 2022 | Ellis Christopher | Chief Operating Officer | Option exercise(M) | 5 | — | $0 |
| Jun 28, 2022 | Ellis Christopher | Chief Operating Officer | Sell(S) | 5 | $6.00 | $30 |
| Jun 28, 2022 | Ellis Christopher | Chief Operating Officer | Option exercise(M) | 5 | — | $0 |
| Jun 24, 2022 | Griffiths Graham | Chief Business Officer | Small acquisition(L) | 100 | $5.87 | $587 |
| Jun 23, 2022 | Griffiths Graham | Chief Business Officer | Sell(S) | 8 | $5.28 | $42 |
| Jun 23, 2022 | Griffiths Graham | Chief Business Officer | Option exercise(M) | 2K | — | $0 |
| Jun 23, 2022 | Griffiths Graham | Chief Business Officer | Option exercise(M) | 2K | — | $0 |
| Jun 23, 2022 | Griffiths Graham | Chief Business Officer | Option exercise(M) | 3K | — | $0 |
| Jun 23, 2022 | Griffiths Graham | Chief Business Officer | Option exercise(M) | 2K | — | $0 |
| Jun 23, 2022 | Griffiths Graham | Chief Business Officer | Option exercise(M) | 3K | — | $0 |
| Jun 23, 2022 | Griffiths Graham | Chief Business Officer | Option exercise(M) | 2K | — | $0 |
| Apr 1, 2022 | Scheeren Joseph | Director | Buy(P) | 10K | $5.09 | $51K |
| Mar 31, 2022 | Hammacher Alex | Director | Buy(P) | 2K | $5.14 | $10K |
| Jan 3, 2022 | Enright William | Chief Executive Officer, Director | Grant(A) | 360K | — | $0 |
| Jan 3, 2022 | Ellis Christopher | Chief Operating Officer | Grant(A) | 80K | — | $0 |
| Jan 3, 2022 | Egorov Georgy | Chief Financial Officer | Grant(A) | 114K | — | $0 |
| Jan 3, 2022 | Griffiths Graham | Chief Business Officer | Grant(A) | 80K | — | $0 |
| Jan 3, 2022 | Marshall Margaret | Chief Medical Officer | Grant(A) | 80K | — | $0 |
| Jan 3, 2022 | Evans Thomas George | Chief Scientific Officer | Grant(A) | 80K | — | $0 |
| Dec 31, 2021 | Hammacher Alex | Director | Buy(P) | 1K | $10.86 | $11K |
| Dec 22, 2021 | Wright Robin | Director | Buy(P) | 10K | $9.97 | $100K |
| May 4, 2021 | Oxford Sciences Innovation plc | 10% Owner | Conversion(C) | 4.8M | — | — |
| May 4, 2021 | Oxford Sciences Innovation plc | 10% Owner | Conversion(C) | 1.7M | — | — |
| May 4, 2021 | Oxford Sciences Innovation plc | 10% Owner | Conversion(C) | 1.7M | — | — |
| May 4, 2021 | Oxford Sciences Innovation plc | 10% Owner | Buy(P) | 600K | $17.00 | $10.2M |
| May 4, 2021 | Oxford Sciences Innovation plc | 10% Owner | Conversion(C) | 4.8M | — | — |
| May 4, 2021 | Oxford Sciences Innovation plc | 10% Owner | Conversion(C) | 1.7M | — | — |
| May 4, 2021 | Oxford Sciences Innovation plc | 10% Owner | Conversion(C) | 1.7M | — | — |
| May 4, 2021 | Phillips Anne M. | Director | Buy(P) | 3K | $17.00 | $51K |
| May 4, 2021 | Scheeren Joseph | Director | Buy(P) | 3K | $17.00 | $51K |
| May 4, 2021 | Ellis Christopher | Chief Operating Officer | Buy(P) | 75 | $17.00 | $1K |
| May 4, 2021 | Wright Robin | Director | Buy(P) | 14K | $17.00 | $238K |
| May 4, 2021 | Griffiths Graham | Chief Business Officer | Buy(P) | 100 | $17.00 | $2K |
| May 4, 2021 | Dawes Karen A | Director | Buy(P) | 2K | $17.00 | $29K |
| May 4, 2021 | Enright William | Chief Executive Officer, Director | Grant(A) | 515K | — | — |
| Apr 30, 2021 | M&G Investment Management Ltd | 10% Owner | Buy(P) | 125K | $14.40 | $1.8M |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: Barinthus Biotherapeutics plc., SEC CIK 0001828185. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under BRNS and shows every filing by that issuer (also filed as VACC).
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-05. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for BRNS